Clinical trials: Exacerbation of COPD
COPD (Chronic Obstructive Pulmonary Disease)
COPD Exacerbation Follow Up
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
- Trial name
- NCT07118306
- Where
- 5 sites in United States
- Volunteers
- 485 people
- Sponsor
- Viz.ai, Inc.
Asthma, COPD
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
This observational study evaluates whether lung sound analysis with LungPass device can be used to differentiate exacerbation and stable state asthma and COPD.
- Trial name
- NCT05145894
- Testing
- Lung auscultation with LungPass device (electronic auscultation)
- Where
- Belarus
- Volunteers
- 200 people
- Sponsor
- Healthy Networks
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL).
- Trial name
- NCT06175065
- Testing
- RLS-0071
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- ReAlta Life Sciences, Inc.
Chronic Obstructive Pulmonary Disease
A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations
The purpose of this study is to observe how the inflammatory pathways differ in subjects with chronic obstructive pulmonary disease (COPD) during an acute exacerbation of COPD (AECOPD).
- Trial name
- NCT01337661
- Where
- Ireland
- Volunteers
- 26 people
- Sponsor
- MedImmune LLC
Chronic Obstructive Pulmonary Disease (COPD)
2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
The aim of the present study is to evaluate the superiority of the fixed triple therapy with BDP/FF/GB at a daily dose of 400/24/50 mcg respectively with that of Ultibro® Breezhaler® (DPI), fixed combination of indacaterol 85 mcg…
- Trial name
- TRIBUTE (NCT02579850)
- Testing
- Central spirometry, COPD assessment test, Local laboratory Assessments
- Where
- Italy
- Volunteers
- 1,532 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan
The purpose of this prospective, epidemiological, cohort study is to evaluate the lung microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese participants
- Trial name
- NCT03957577
- Testing
- Prospective observational cohort study
- Where
- 13 sites in Japan
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation Acute
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation.
- Trial name
- NCT05400369
- Testing
- Sitafloxacin, Moxifloxacin Hydrochloride
- Where
- 18 sites in China
- Volunteers
- 140 people
- Sponsor
- Daiichi Sankyo
Chronic Bronchitis
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
A study to assess the safety and efficacy of moxifloxacin compared to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbation of chronic bronchitis.
- Trial name
- NCT00656747
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Amoxicillin clavulanic acid
- Where
- 220 sites in Andorra, Argentina and 29 more
- Volunteers
- 1,372 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease (COPD)
Tezepelumab COPD Exacerbation Study
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- COURSE (NCT04039113)
- Testing
- Tezepelumab
- Where
- 91 sites in United States, Canada and 8 more
- Volunteers
- 337 people
- Sponsor
- AstraZeneca
COPD
High Risk Populations Among COPD Patients in Japan
The patients with complications of COPD and asthma have features mixed with two diseases, COPD and asthma. Therefore, the outcomes are worsened if the patients with COPD have symptoms overlapped with asthma, however, no…
- Trial name
- NCT02413359
- Where
- Japan
- Volunteers
- 1,016 people
- Sponsor
- AstraZeneca
Respiratory Disorders
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD…
- Trial name
- NCT01360398
- Testing
- Blood sample, Sputum sample, Nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation
Early Extubation by ECCO2R Compared to IMV in Patients with Severe Acute Exacerbation of COPD
The study aims to investigate if veno-venous (vv)-extracorporeal carbon dioxide Removal (ECCO2R) is capable of reducing mortality and/or severe disability at day 60 after randomisation in patients with severe acute exacerbation…
- Trial name
- X-COPD (NCT03584295)
- Testing
- Extracorporeal carbon dioxide removal, Conventional Care
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Xenios AG
Chronic Obstructive Pulmonary Disease (COPD)
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce…
- Trial name
- MISSION (NCT07587658)
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 754 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation
Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER
The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).
- Trial name
- UTAPE BPCO (NCT01857947)
- Testing
- AECOPD Mr proADM
- Where
- 2 sites in France
- Volunteers
- 370 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297115
- Testing
- Roflumilast
- Where
- 287 sites in United States, Canada and 6 more
- Volunteers
- 1,568 people
- Sponsor
- AstraZeneca
Asthma, Copd
Inhaler Trainer Efficacy Study
This will be a randomized, controlled, clinical trial. The investigators aim to determine the feasibility of and efficacy of the Inhaler Trainer Device for ongoing inhaler skill training.
- Conditions
- Asthma, Copd, Acute Exacerbation of COPD
- Trial name
- NCT06461403
- Testing
- Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Koronis Biomedical Technologies
COPD, COPD Exacerbation
A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination
Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; we will perform a retrospective analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to…
- Trial name
- RETRIEVE (NCT03858348)
- Where
- Greece
- Volunteers
- 1,000 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Disease, Chronic Obstructive
Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
This is a 12 month randomized, open-label, parallel-group study to obtain data on the frequency and variability of exacerbations in severe and very severe Chronic Obstructive Pulmonary Disease (COPD) patients (Global Initiative…
- Trial name
- NCT00527826
- Testing
- Salmeterol / Fluticasone (50/500 µg) BID fixed combination, Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers
- Where
- 23 sites in Germany
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
COPD
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.
- Trial name
- NCT01645800
- Testing
- Lysozyme hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 408 people
- Sponsor
- Eisai Co., Ltd.
Chronic Obstructive Pulmonary Disease, COPD
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00076089
- Testing
- Roflumilast
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca